StockData
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. (NRXP) shareholders

NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.45+0.30 (+13.95%)

Close on Nov 17, 2026Market cap $106.08MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
26.9%
12M of 43M shares
Institutional holders
47
19 new, 5 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
B Group Capital LLC
Joint filing with The B Group, Inc. (12.62%), Branden B. Muhl (12.62%)
3,000,00012.62%13G (passive)Aug 18, 2025
Amin Nathoo
Joint filing with Anson Funds Management LP (9.30%), Anson Management GP LLC (9.30%) and 3 more
1,604,9759.30%13G (passive) amendmentJun 30, 2025
Anson Management GP LLC
Joint filing with Anson Funds Management LP (7.00%), Tony Moore (7.00%) and 3 more
1,179,0617.00%13G (passive)Mar 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NRXPValueChange% of portfolio
B Group, Inc.4,091,7679.45%$16.74M+1,091,7677.86%
Vanguard Capital Management LLC1,618,1593.74%$6.62M+457,9750.00%
Ameriprise Financial Inc928,7282.15%$3.80MNew0.00%
Balyasny Asset Management L.P.893,8642.06%$3.66MNew0.00%
Citadel Advisors LLC680,0431.57%$2.78MNew0.00%
AdvisorShares Investments LLC659,0181.52%$2.70M+238,5510.33%
Commonwealth Equity Services, LLC454,4181.05%$1.86M+56,9870.00%
UBS Group AG423,1150.98%$1.73M+397,8880.00%
Geode Capital Management, LLC314,6590.73%$1.29M+4,5470.00%
BlackRock, Inc.220,4600.51%$901.68K+121,4650.00%
Marshall Wace, Llp194,5800.45%$795.83KNew0.00%
Vanguard Fiduciary Trust Co182,7180.42%$747.32K+13,1380.00%
Jane Street Group, LLC119,0180.27%$486.78K+74,8660.00%
Bleakley Financial Group, LLC117,2160.27%$479.41K+120.01%
State Street Corp116,0840.27%$474.78K+29,1000.00%
Hrt Financial LP100,7240.23%$411.00KNew0.00%
Northern Trust Corp62,9510.15%$257.47K+19,4820.00%
Chicago Partners Investment Group LLC46,3880.11%$190.66K+11,9090.00%
Quadrature Capital Ltd43,6050.10%$178.34KNew0.00%
One Wealth Management Investment & Advisory Services, LLC43,3090.10%$177.13K–0.19%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20264712M26.9%19 / 174 / 56M0M
Q1 2026336M14.3%11 / 131 / 45M3M
Q4 2025285M12.1%7 / 710 / 32M1M
Q3 2025244M9.1%4 / 133 / 51M0M
Q2 2025253M6.9%5 / 104 / 21M0M
Q1 2025222M5.2%4 / 65 / 71M0M
Q4 2024251M2.4%10 / 43 / 30M0M
Q3 2024181M1.6%4 / 43 / 40M0M
Q2 2024191M1.2%19 / 00 / 01M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

13 funds held NRXP in Q2 2026, 89% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of NRXPValue% of fundAs of
Vanguard Total Stock Market Index Fund1,267,1022.93%$5.18M0.00%Jun 30, 2026
AdvisorShares Psychedelics ETF659,0181.52%$2.70M6.07%Jun 30, 2026
Vanguard Extended Market Index Fund291,3930.67%$1.19M0.00%Jun 30, 2026
Fidelity Extended Market Index Fund131,2990.30%$580.34K0.00%May 31, 2026
iShares Micro-Cap ETF104,9690.24%$429.32K0.03%Jun 30, 2026
Fidelity Series Total Market Index Fund48,1230.11%$212.70K0.00%May 31, 2026
Fidelity Total Market Index Fund30,8120.07%$136.19K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund21,9760.05%$97.13K0.00%May 31, 2026
Vanguard Balanced Index Fund21,7170.05%$88.82K0.00%Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund15,4590.04%$63.23K0.00%Jun 30, 2026
1290 VT Micro Cap Portfolio7,1130.02%$29.09K0.01%Jun 30, 2026
Victory Extended Market Index Fund4,2750.01%$13.47K0.00%Jul 31, 2026
Total Stock Market Index Trust6340.00%$2.59K0.00%Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund-1,211-0.00%-$4.95K-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jonathan C. JavittCEO and Chairman, Director1,516,8343.50%Nov 4, 2026
Michael S. AbramsChief Financial Officer––Nov 4, 2026
Joseph Michael CasperChief Operating Officer––Feb 17, 2026
Patrick John FlynnDirector39,4590.09%Sep 10, 2025
Chaim HurvitzDirector2,214,7935.12%Sep 10, 2025
Dennis McBrideDirector––Sep 10, 2025
B Group, Inc.10% owner3,000,0006.93%Aug 21, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jonathan C. Javitt
Chairman and Chief Scientist, Director, 10% owner
Dec 17, 2024Buy+40,000$1.17$46.80K84,634
Aaron Gorovitz
Director
Aug 30, 2023Buy+35,000$0.32$11.20K105,000
Chaim Hurvitz
Director
Aug 30, 2023Buy+70,000$0.29$20.30K570,000
Jonathan C. Javitt
Chief Scientist, Director, 10% owner
Aug 23, 2023Buy+100,000$0.33$33.00K446,332
Jonathan C. Javitt
Chief Scientist, Director, 10% owner
Aug 22, 2023Buy+200,000$0.32$64.00K346,332
Stephen H. Willard
CHIEF EXECUTIVE OFFICER, Director
Dec 16, 2022Buy+50,000$1.17$58.50K50,000
Voorhees Seth Van
CHIEF FINANCIAL OFFICER
Dec 16, 2022Buy+30,000$1.10$33.00K46,337
Jonathan C. Javitt
Director, 10% owner
Dec 14, 2022Gift−300,000––14,468,329
Jonathan C. Javitt
Director, 10% owner
Dec 7, 2022Sale−400,000$1.00$400.00K12,899,997
Daniel C. Javitt
10% owner
Nov 30, 2022Sale(10b5-1 plan)−8,441$1.50$12.66K9,634,793
Daniel C. Javitt
10% owner
Nov 29, 2022Sale(10b5-1 plan)−13,730$1.50$20.60K9,643,234
Patrick John Flynn
Director
Nov 28, 2022Buy+2,500$1.25$3.13K37,709
Patrick John Flynn
Director
Nov 28, 2022Buy+2,500$1.25$3.13K37,709
Patrick John Flynn
Director
Nov 28, 2022Buy+2,500$1.24$3.10K40,209
Patrick John Flynn
Director
Nov 28, 2022Buy+1,750$1.25$2.19K1,750
Patrick John Flynn
Director
Nov 28, 2022Buy+2,500$1.25$3.13K40,209
Voorhees Seth Van
CHIEF FINANCIAL OFFICER
Nov 25, 2022Buy+7,021$1.11$7.79K16,337
Voorhees Seth Van
CHIEF FINANCIAL OFFICER
Nov 25, 2022Buy+8,716$1.12$9.76K8,716
Voorhees Seth Van
CHIEF FINANCIAL OFFICER
Nov 25, 2022Buy+600$1.10$6609,316
Voorhees Seth Van
CHIEF FINANCIAL OFFICER
Nov 25, 2022Buy+8,716$1.12$9.76K8,716
Voorhees Seth Van
CHIEF FINANCIAL OFFICER
Nov 25, 2022Buy+600$1.10$6609,316
Voorhees Seth Van
CHIEF FINANCIAL OFFICER
Nov 25, 2022Buy+7,021$1.11$7.79K16,377
Chaim Hurvitz
Director
Nov 18, 2022Buy+40,408$1.10$44.45K500,000
Chaim Hurvitz
Director
Nov 18, 2022Buy+40,408$1.10$44.45K500,000
Chaim Hurvitz
Director
Nov 17, 2022Buy+171,780$1.08$185.52K459,592
Chaim Hurvitz
Director
Nov 17, 2022Buy+171,780$1.08$185.52K459,592
Daniel C. Javitt
10% owner
Nov 17, 2022Sale(10b5-1 plan)−33,018$1.05$34.67K9,656,964
Chaim Hurvitz
Director
Nov 16, 2022Buy+287,812$0.99$284.93K287,812
Chaim Hurvitz
Director
Nov 16, 2022Buy+287,812$0.99$284.93K287,812
Daniel C. Javitt
10% owner
Nov 16, 2022Sale(10b5-1 plan)−133,719$1.02$136.39K9,689,982
Daniel C. Javitt
10% owner
Nov 11, 2022Sale(10b5-1 plan)−49,200$1.01$49.69K9,823,701
Daniel C. Javitt
10% owner
Jul 29, 2022Sale−784,063$1.01$791.90K9,872,901
Daniel C. Javitt
10% owner
Jul 1, 2022Gift−2,000,000––10,656,964
Daniel C. Javitt
10% owner
Jun 7, 2022Sale−86,459$0.65$56.20K12,656,964
Daniel C. Javitt
10% owner
Jun 6, 2022Sale−115,657$0.67$77.49K12,743,423
Daniel C. Javitt
10% owner
Jun 3, 2022Sale−243,596$0.70$170.52K12,859,080
Jonathan C. Javitt
Chief Scientist, Director, 10% owner
Jun 1, 2022Buy+100,000$0.58$58.00K146,332
Jonathan C. Javitt
Chief Scientist, Director, 10% owner
Jun 1, 2022Buy+100,000$58.00$5.80M146,332
Robert Besthof
Chief Comm. & Patient Officer
Sep 15, 2021Sale−40,000$11.76$470.40K23,710
Alessandra Daigneault
General Counsel & Secretary
Sep 2, 2021Option exercise+18,420$3.07$56.55K18,420
Alessandra Daigneault
General Counsel & Secretary
Sep 2, 2021Option exercise+13,164$3.07$40.41K31,584
Herbert Raymond McMaster
Director
Aug 26, 2021Option exercise+18,300$2.22$40.63K18,300
Alessandra Daigneault
General Counsel & Secretary
Aug 23, 2021Sale−33,715$13.11$442.00K0
Alessandra Daigneault
General Counsel & Secretary
Aug 19, 2021Option exercise+27,395$3.07$84.10K33,715
Robert Besthof
Chief Comm. & Patient Officer
Aug 16, 2021Option exercise+63,710$0.20$12.74K63,710
Daniel C. Javitt
10% owner
Jul 16, 2021Gift−434,594––13,102,676
Daniel C. Javitt
10% owner
Jul 16, 2021Gift−434,594––13,537,270
Patrick John Flynn
Director
May 24, 2021Award+362,332––362,332
Patrick John Flynn
Director
May 24, 2021Award+35,209––35,209
Patrick John Flynn
Director
May 24, 2021Award+35,209––35,209
Chaim Hurvitz
Director
May 24, 2021Award+208,443––208,443
Chaim Hurvitz
Director
May 24, 2021Award+1,436,350––1,436,350
Aaron Gorovitz
Director
May 24, 2021Award+8,336––8,336
Aaron Gorovitz
Director
May 24, 2021Award+8,336––8,336
Aaron Gorovitz
Director
May 24, 2021Award+8,336––8,336
Aaron Gorovitz
Director
May 24, 2021Award+16,678––16,678
Sharon Glied
Director
May 24, 2021Award+13,168––13,168
Jonathan C. Javitt
Chief Executive Officer, Director, 10% owner
May 24, 2021Award+46,332––46,332
Jonathan C. Javitt
Chief Executive Officer, Director, 10% owner
May 24, 2021Award+1,422,000––1,422,000
Jonathan C. Javitt
Chief Executive Officer, Director, 10% owner
May 24, 2021Award+13,348,997––13,348,997

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
28.64%
10M shares short
Days to cover
4.6
At 2M shares a day
Change since last report
+5.1%
From 10M shares
Short volume, 20 days
60.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NRX Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 97,603 shares on Sep 24, 2026 over the last 90 days.

See a number that looks wrong?